Oncolytics Biotech Inc. (TSE:ONC – Get Free Report) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of C$14.90 and traded as low as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares trading hands.
Oncolytics Biotech Stock Performance
The business has a fifty day simple moving average of C$14.90 and a 200-day simple moving average of C$14.90. The company has a quick ratio of 8.86, a current ratio of 2.88 and a debt-to-equity ratio of 14.58. The firm has a market cap of C$1.50 billion, a P/E ratio of -40.27 and a beta of 0.80.
About Oncolytics Biotech
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.
Further Reading
- Five stocks we like better than Oncolytics Biotech
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
